Olencki, T <br/><br/>
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.  [electronic resource] 

 -  Journal of cancer research and clinical oncology  May 2001 
 - 319-24 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0171-5216 
<br/><br/><label>Standard No.: </label>10.1007/s004320000211  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anorexia--chemically induced<br/>Antimetabolites, Antineoplastic--administration & dosage<br/>Carcinoma, Renal Cell--drug therapy<br/>Chills--chemically induced<br/>Combined Modality Therapy<br/>Death, Sudden, Cardiac--etiology<br/>Dose-Response Relationship, Drug<br/>Fatigue--chemically induced<br/>Female<br/>Fever--chemically induced<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Immunotherapy<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Interleukin-2--administration & dosage<br/>Kidney Neoplasms--drug therapy<br/>Life Tables<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Nausea--chemically induced<br/>Recombinant Proteins--administration & dosage<br/>Survival Analysis<br/>Thrombocytopenia--chemically induced<br/>Vomiting--chemically induced